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Effect of an antiretroviral regimen containing ritonavir boosted
lopinavir on intestinal and hepatic CYP3A, CYP2D6 and
P-glycoprotein in HIV-infected patients
Abstract
This study aimed to quantify the inhibition of cytochrome P450 (CYP3A), CYP2D6, and P-glycoprotein
in human immunodeficiency virus (HIV)-infected patients receiving an antiretroviral therapy (ART)
containing ritonavir boosted lopinavir, and to identify factors influencing ritonavir and lopinavir
pharmacokinetics. We measured activities of CYP3A, CYP2D6, and P-glycoprotein in 28 patients
before and during ART using a cocktail phenotyping approach. Activities, demographics, and genetic
polymorphisms in CYP3A, CYP2D6, and P-glycoprotein were tested as covariates. Oral midazolam
clearance (overall CYP3A activity) decreased to 0.19-fold (90% confidence interval (CI), 0.15-0.23),
hepatic midazolam clearance and intestinal midazolam availability changed to 0.24-fold (0.20-0.29) and
1.12-fold (1.00-1.26), respectively. In CYP2D6 extensive metabolizers, the plasma ratio
AUC(dextromethorphan)/AUC(dextrorphan) increased to 2.92-fold (2.31-3.69). Digoxin area under the
curve (AUC)(0-12) (P-glycoprotein activity) increased to 1.81-fold (1.56-2.09). Covariates had no major
influence on lopinavir and ritonavir pharmacokinetics. In conclusion, CYP3A, CYP2D6, and
P-glycoprotein are profoundly inhibited in patients receiving ritonavir boosted lopinavir. The covariates
investigated are not useful for a priori dose selection.
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Abstract  
This study aimed to quantify the inhibition of CYP3A, CYP2D6 and P-glycoprotein in HIV-
infected patients receiving an antiretroviral therapy containing ritonavir boosted lopinavir, and 
to identify factors influencing ritonavir and lopinavir pharmacokinetics.  
We measured activities of CYP3A, CYP2D6 and P-glycoprotein in 28 patients before and 
during antiretroviral therapy using a cocktail phenotyping approach. Activities, demographics, 
and genetic polymorphisms in CYP3A, CYP2D6, and P-glycoprotein were tested as 
covariates.  
Oral midazolam clearance (overall CYP3A activity) decreased to 0.19-fold (90% confidence 
interval, 0.15-0.23), hepatic midazolam clearance and intestinal midazolam availability 
changed to 0.24-fold (0.20-0.29), and 1.12-fold (1.00-1.26), respectively. In CYP2D6 
extensive metabolizers, the plasma ratio AUCdextromethorphan/AUCdextrorphan increased to 2.92-
fold (2.31-3.69). Digoxin AUC0-12 (P-glycoprotein activity) increased to 1.81-fold (1.56-
2.09). Covariates had no major influence on lopinavir and ritonavir pharmacokinetics.  
In conclusion, CYP3A, CYP2D6, and P-glycoprotein are profoundly inhibited in patients 
receiving ritonavir boosted lopinavir. The covariates investigated are not useful for a-priori 
dose selection.  
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Introduction  
In the treatment of HIV-infected patients, most antiretroviral therapy regimens include 
protease inhibitors, of which ritonavir boosted lopinavir (Kaletra®) is among the most widely 
used (1). Lopinavir has a negligible bioavailability unless the cytochrome P450 (CYP) 3A 
enzymes, which mediate its extended first pass metabolism, are inhibited by low-dose 
ritonavir. In vitro investigations, studies in laboratory animals and in healthy volunteers 
suggest that ritonavir boosted lopinavir influences the activities of other enzymes like 
CYP2D6, the second most important drug metabolizing CYP enzyme in the liver, and of drug 
transporters like the efflux transporter P-glycoprotein (2-5). Thus, beyond (necessary) CYP3A 
inhibition, ritonavir boosted lopinavir is at risk to cause drug-drug interactions by inhibition 
of several other structures. In HIV infected patients, however, the effect of the combination on 
enzyme and transporter activities has not yet been quantified.  
 
As an additional problem, pharmacokinetics of protease inhibitors (PI) show high 
interindividual variability that may cause suboptimal drug exposure, poor treatment response 
or toxicity. The knowledge of factors which influence this variability may be useful to 
optimize HIV therapy. Only few in vivo trials focus on the influence of the individual 
activities of CYP3A, CYP2D6 and P-glycoprotein on PI pharmacokinetics (2,4,6-8). Most of 
these studies have been carried out in healthy volunteers or in laboratory animals.  
 
The activities of CYP3A, CYP2D6, and P-glycoprotein are in part genetically determined. 
Functionally deficient CYP2D6 and the CYP3A5*3 alleles were associated with alterations in 
the metabolism of some PIs (9-12), while for relationships between P-glycoprotein genotypes 
and pharmacokinetics of different PIs, results are contradictory (12-17). For lopinavir and 
ritonavir, information on genetic influences is sparse.  
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Hence, the present study had two aims. One purpose was to quantify the effect of ritonavir 
boosted lopinavir on the activities of the most important cytochrome P450 enzymes, namely 
CYP3A at the intestinal and the hepatic expression sites, CYP2D6, and of P-glycoprotein in 
HIV-infected individuals. The other purpose was to identify factors of influence on the 
pharmacokinetics of ritonavir and lopinavir which may be used for a-priori dose 
individualization. To this end, the combined impact of demographic factors, genetic 
polymorphisms and the activities of CYP3A, CYP2D6, and P-glycoprotein on the 
pharmacokinetics of lopinavir and ritonavir was assessed.  
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Material and Methods:  
Study design and study population  
This prospective, open, non-randomized, two-period trial was conducted in 30 male and 
female treatment-naïve HIV-infected patients, of which 28 completed the trial (table 1). The 
activities of hepatic and intestinal CYP3A, CYP2D6 and P-glycoprotein were investigated 
twice by using a phenotyping cocktail, once before (period 1), and once at least 14 days after 
the start (period 2) of an antiretroviral regimen (ART) containing 400 mg lopinavir + 100 mg 
ritonavir (3 capsules Kaletra®, Abbott, Wiesbaden, Germany) twice daily. Together with 
Kaletra®, the nucleoside reverse transcriptase inhibitors zidovudine and lamivudine (300 mg 
and 150 mg, respectively, twice daily, Combivir®, GlaxoSmithKline, Munich, Germany) 
were started in all patients. The subjects were asked regularly about adherence to the 
antiretroviral therapy. All drug intakes on the phenotyping days were supervised. The main 
exclusion criteria were: any relevant pathological finding not explained by the HIV infection, 
any relevant history or current condition that might interfere with pharmacokinetics, hepatic 
or renal diseases or dysfunctions, drug and alcohol abuse, pregnancy and breast-feeding. 
Patients using a medication or natural product (including grapefruit and herbal remedies) 
known to potentially interfere with CYP3A, CYP2D6 and P-glycoprotein were not included. 
The study was endorsed by the Ethics Committee of the University of Cologne, Germany, and 
conducted in accordance with the laws of Germany. Written informed consent was obtained 
from each patient.  
The phenotyping cocktail consisted of 1.5 mg midazolam hydrochloride (CYP3A, 
Dormicum® V 5mg/5mL, Hoffmann-La Roche, Grenzach-Wyhlen, Germany), 30 mg 
dextromethorphan hydrobromide (CYP2D6, Hustenstiller-ratiopharm®, ratiopharm, Ulm, 
Germany), and 0.5 mg digoxin (P-glycoprotein, Lanicor®, Roche) administered orally in the 
morning either alone or together with the antiretrovirals. Four hours later, 1.0 mg midazolam 
hydrochloride (hepatic CYP3A, Dormicum®, Roche), was given intravenously. Midazolam is 
page 6  
the best validated probe for CYP3A activity both at the hepatic and the intestinal expression 
sites. Dextromethorphan and digoxin are established probes for CYP2D6 and P-glycoprotein 
activity, respectively (18-20). Midazolam, digoxin, dextromethorphan, and dextrorphan were 
quantified in plasma before and up to 12 h after oral dosing (22 samples). Only during period 
2, lopinavir and ritonavir were quantified in plasma up to 12 h after the morning dose of 
Kaletra® (11 samples). Plasma was stored at –80°C until analysis.  
 
Analytical methods  
Midazolam, dextromethorphan, and dextrorphan in plasma 
After thawing, 300 µL of 100 mM NaHCO3 (pH 10.5), 50 µL water, and 50µL of internal 
standard (0.172 µg/mL dextromethorphan-d3 (HSPC, Westminster, CA, USA) and 0.126 
µg/mL [13C4, 14N] labelled midazolam maleate (Ultrafine Chemicals, Manchester, UK)) were 
added to 200 µL plasma. Thereafter, 750 µL of ethyl acetate were added, the sample was 
vortex mixed and centrifugated (18,600 g, 10 min). Then, 600 µL of the upper layer were 
mixed with 100 µL of a 1% formic acid solution, vortex mixed, centrifugated, and 20 µL of 
the aqueous phase were injected into the LC-MS/MS system. The LC-MS/MS system 
consisted of a Surveyor® MS pump and autosampler (Thermo Electron, San Jose, CA), fitted 
with a tempered tray (10°C) and column oven (30°C), coupled to a triple quadrupole mass 
spectrometer (TSQ® Quantum, Thermo Electron) with an electrospray ionization (ESI) 
source, operated in the positive ion mode. Nitrogen was used as sheath and auxiliary gas, 
while argon served as collision gas. The system was operated in the selected reaction 
monitoring mode. The Xcalibur® software (rev. 1.3, Thermo Electron) was used for 
instrument control, data acquisition and evaluation. For chromatographic separation, a 
Hypersil Gold® column (50 x 2.1 mm, 5µm, Thermo Electron, Runcorn, UK) with pre-
column was used. Liquid chromatography was performed with a constant flow rate of 300 
µL/min and a solvent gradient: after an isocratic flow of 95% of 0.1% aqueous formic acid 
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and 5% pure methanol for 30 sec, the organic solvent was increased to 90% during 1 min. 
This composition was maintained for 1.5 min. Initial conditions were restored within 30 sec 
and maintained for additional 30 sec. Dextrorphan was eluted at 2.6 min. All other analytes 
were eluted at 2.9 min. The following parent/product ions were monitored: midazolam m/z 
326.10→291.10, labelled midazolam m/z 331.00→296.30, dextromethorphan m/z 
272.40→171.16, dextrorphan m/z 258.40→157.15, and dextromethorphan-d3 m/z 
275.00→171.16. Quantification of analytes was carried out using peak area ratios of the 
analyte and its respective internal standard. The lower limits of quantification were as 
follows: midazolam 0.306 µg/L, dextromethorphan 0.103 µg/L, and dextrorphan 0.101 µg/L. 
The method was fully validated according to international guidelines. Precision ranged from 
2.6% to 6.3% for midazolam, from 3.2% to 7.8% for dextromethorphan, and from 4.7% to 
9.2% for dextrorphan, while accuracy was 104.4% to 106.4%, 101.8% to 102.9%, and 97.4% 
to 99.5% for the three analytes, respectively. 
 
Lopinavir and ritonavir in plasma  
Both analytes were quantified in plasma using a HPLC-UV method with a lower limit of 
quantification of 0.07 mg/L for lopinavir and 0.05 mg/L for ritonavir as described (21).  
 
Digoxin in plasma  
Digoxin concentrations were measured on a Roche/Hitachi MODULAR P analyzer using the 
Tina-quant® digoxin immunoassay (Roche Diagnostics GmbH, Mannheim, Germany), with a 
lower limit of quantification of 0.15 ng/mL.  
 
Genotyping  
Genomic DNA from EDTA containing blood samples was extracted using the QIAamp DNA 
Blood Mini Kit (Qiagen, Hilden, Germany). Analyses for the CYP2D6 alleles *3, *4, *5, *6, 
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and the duplication allele were performed with PCR-RFLP-methods as described (22). 
Determination of these non-functional CYP2D6 alleles has been shown to be sufficient to 
correctly identify 95% of the poor metabolizers (PM) according to CYP2D6 (22). Individuals 
were assessed to the PM group when carrying two inactive CYP2D6 alleles (CYP2D6*3, *4, 
*5, or *6), to the intermediate (IM) group when carrying one active and one inactive allele 
(heterozygous carrier), to the extensive metabolizer (EM) group when none of the variant 
alleles was found, and to the ultrarapid metabolizer (UM) group when carrying a CYP2D6 
gene duplication in combination with two active alleles.  
Genotyping for the CYP3A5*3 allele was done as described using a melting curve analysis 
technique (23,24).  
Genotyping for P-glycoprotein was done by direct sequencing of the MDR1 exons 2, 12, 21 
and 26, including the single nucleotide polymorphisms C-4T, G-1A, A61G (Asn21Asp), 
C1236T (synonymous), G2677T (Ala893Ser), G2677A (Ala893Thr), and C3435T 
(synonymous). The oligonucleotides used for amplification were (5’ first): 
CCCCCAACTCTGCCTTCGTG (exon 2, forward), CTCGCAACTATGTAAACTATGAAA 
(exon 2, reverse), TGGGCACAAACCAGATAATAT (exon 12, forward), 
CCCGTAGAAACCTTACATT (exon 12, reverse), TGCCGTGATTAATGAAGGT (exon 21, 
forward), TGGGGAGGAAGGAAGAACAGT (exon 21, reverse), 
TTGGCAGTTTCAGTGTAAGAA (exon 26, forward), and 
GTGTGGCCAGATGCTTGTATA (exon 26, reverse). All PCR amplifications were carried 
out in 50 µL reaction mixtures containing 100 ng of genomic DNA, 1x buffer, 2.3 mM 
MgCl2, 0.5 µM of each primer, 0.8 mM of dNTPs, and 2.5 U HotStarTaq DNA Polymerase 
(Qiagen). After purification, PCR products were sequenced using the BigDye Terminator 
Cycle Sequencing Ready Reaction Kit v2.0 (Applied Biosystems, Foster City, CA). 
Sequencing analysis was performed on a Genetic Analyzer 3100 capillary sequencer (Applied 
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Biosystems) and pairwise sequence alignments were done with GenBank sequence 
NM_000927 using MT Navigator PPC and Edit View software (Applied Biosystems).  
 
Pharmacokinetic calculations  
Noncompartmental methods were used for pharmacokinetic analysis (WinNonlinTM 
Professional 5.0.1, Pharsight corp., Cary, NC), except for midazolam. The areas under the 
plasma concentration time curves (AUC) were calculated using the log-linear method. 
Pharmacokinetics of lopinavir and ritonavir were assessed during one dosing interval in 
steady-state. For digoxin, dextromethorphan, and dextrorphan, AUC values from dosing up to 
12 h thereafter without extrapolation to infinity were reported. The early portion of the 
digoxin AUC and the digoxin Cmax have been used earlier as parameters to characterize the 
intestinal P-glycoprotein activity (25-27). The fraction of AUCdextromethorphan and AUCdextrorphan 
based on extrapolation was above 20% in most subjects and varied considerably between 
subjects, which justified the use of AUC values without extrapolation, since most 
dextromethorphan-based CYP2D6 phenotyping metrics proposed in literature are based on 
parameters obtained up to 8 h after dosing (19). As a parameter for CYP2D6 activity, the 
molar ratio of the plasma AUCdextromethorphan over the plasma AUCdextrorphan was chosen. The 
individual activity of (intestinal) P-glycoprotein was assessed with the digoxin AUC0-12h and 
the digoxin Cmax values.  
To estimate the CYP3A activity separately for the intestinal and hepatic expression sites, the 
pharmacokinetics of midazolam were assessed with a compartmental approach by population 
pharmacokinetic analysis using the nonlinear mixed effect modeling program NONMEM® 
version V (level 1.1, GloboMax, Ellicot City, MD) as described earlier (28). Briefly, a one 
compartment model without intraindividual variation was stepwise expanded to more 
complex models. The best model was a two-compartment model with first-order absorption 
(subroutine ADVAN4 TRANS4), interindividual variation in each parameter except in 
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intercompartmental clearance and peripheral volume of distribution, and appropriate error 
modeling for the interindividual and the residual variability (which included intraindividual 
variability). The midazolam clearance after intravenous dosing (a standard parameter for 
hepatic CYP3A activity) and the oral midazolam availability (F) were directly modeled by the 
program and were estimated separately for each study period. The apparent oral midazolam 
clearance was calculated as Cl / F, and reflects both hepatic and intestinal CYP3A activities. 
As parameter for intestinal CYP3A activity, the intestinal midazolam availability (i.e. the ratio 
of oral availability over hepatic availability) was calculated as described earlier (28,29). 
Individual doses were calculated from weights of the application devices with and without 
midazolam solutions, and were included in the analysis.  
 
Statistical analysis  
Values are given as geometric means and geometric coefficients of variation unless otherwise 
stated. A p-value of <0.05 was considered statistically significant. The interactions between 
antiretroviral therapy and phenotyping probes were evaluated as a bioequivalence problem 
(30). Point estimates for the true ratios of individual parameters in the periods without 
(reference) and with antiretrovirals (test) and the corresponding 90% confidence intervals (CI) 
were calculated. An interaction was assumed to be absent when both the point estimate and 
the 90% CI were entirely within the bioequivalence boundaries of 80 – 125 % of the reference 
values.  
For comparisons between two variables, correlation analyses, Mann-Whitney-U tests, or 
Kruskal-Wallis tests were carried out. Univariate linear effect models were used to investigate 
the extent of influence of i) demographics and genetics on the activities of CYP3A, CYP2D6 
and P-glycoprotein, and ii) demographics, genetics, enzyme and transporter activities on 
lopinavir and ritonavir pharmacokinetics. An influence was judged as clinically relevant if it 
explained 30% or more of the interindividual variability. No adjustment for multiple testing 
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was done, since the target variables were considered mutually independent, however, several 
potential covariates were tested for one target, so that the models were exploratory in nature. 
As factors of potential influence, age, weight, height, Body Mass Index, transporter and 
enzyme activities were included as covariates, while gender, race, and genotypes were 
included as fixed factors. For statistical analysis, WinNonlinTM and SPSS®, release 11.0.1 
(SPSS Inc., Chicago, IL) were used.  
 
Sample size calculation  
A sample size of 30 patients was calculated using WinBiAS (Version 7.01, epsilon Verlag, 
Darmstadt, Germany) and allowed to test whether the interindividual variability in PI 
pharmacokinetics was determined to at least 30% each by CYP3A, CYP2D6 or P-
glycoprotein activity with a power of 90% on a significance level of 0.05 using linear 
correlation analysis.  
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Results  
After at least two weeks of twice daily intake of 400 mg lopinavir and 100 mg ritonavir (3 
capsules Kaletra®) together with zidovudine and lamivudine, the parameters for CYP3A 
activity showed profound enzyme inhibition (figure 1, figure 2, table 2). The extent of 
inhibition differed between the two expression sites of CYP3A: while hepatic midazolam 
clearance, a parameter for hepatic CYP3A activity, reduced to 0.24-fold (90% confidence 
interval, 0.20-fold – 0.29-fold) during antiretroviral therapy (ART), intestinal midazolam 
availability, a parameter for intestinal CYP3A activity, increased 1.12-fold (90% confidence 
interval, 1.00-fold – 1.26-fold) from 78% to 87%. The apparent oral midazolam clearance, a 
parameter reflecting both hepatic and intestinal CYP3A activity, decreased to 0.19-fold (90% 
confidence interval, 0.15-fold – 0.23-fold). The CYP3A5 genotype (table 1) did not influence 
any CYP3A metric (Kruskal-Wallis tests).  
 
In 24 patients who possessed at least one functional CYP2D6 allele, a 2.92-fold increase in 
the plasma metabolic ratio AUCdextromethorphan / AUCdextrorphan (90% confidence interval, 2.31-
fold – 3.69-fold) indicated a decrease in the mean CYP2D6 activity (figure 3, figure 4, table 
2). In the four genotypically poor metabolizers, the mean metabolic ratio did not change, but 
the between-subject variability was considerable (point estimate, 1.34-fold, 90% confidence 
interval, 0.41-fold – 4.36-fold). As expected, CYP2D6 genotypes had a major impact on the 
AUCdextromethorphan and the plasma metabolic ratio both before (p = 0.009 and p = 0.006, 
respectively) and during ART (p = 0.005 and p = 0.006, respectively, Kruskal-Wallis tests for 
groups of CYP2D6 genotypes).  
 
Also, the mean P-glycoprotein activity was markedly reduced: the digoxin AUC0-12 increased 
to 1.81-fold (90% confidence interval, 1.56-fold – 2.09-fold, figure 5, figure 6, table 2). Only 
gender had a significant influence on digoxin AUC both before (4.68 µg/L*h in males 
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(coefficient of variation, CV, 42%), and 6.38 µg/L*h in females (CV 35%), p = 0.021) and 
during antiretroviral therapy (8.89 µg/L*h in males (CV 21%), and 11.26 µg/L*h in females 
(CV 18%), p = 0.016), and explained 15% and 17% of the variability in this parameter, 
respectively. The MDR1 genotypes did not significantly influence digoxin AUC0-12 or Cmax.  
 
The geometric mean lopinavir AUC0-12 in steady-state was 66.4 mg/L*h (geometric CV, 
80%), while lopinavir Cmax and Clast reached 9.23 mg/L (CV 58%) and 2.40 mg/L (CV 155%), 
respectively. The geometric mean ritonavir plasma exposure in steady-state (AUC0-12) was 
2.90 mg/L*h (CV 72%), and the mean ritonavir Cmax and Clast attained 0.51 mg/L (CV 70%) 
and 0.10 mg/L (CV 74%), respectively. Lopinavir and ritonavir exposure were correlated (r2 = 
0.464, p = 0.00007).  
 
In the evaluation of factors of influence on the pharmacokinetics of lopinavir and ritonavir, 
the sole factor with a significant influence on any parameter of lopinavir was age, which 
explained 11% of the variability in lopinavir AUC0-12 (AUClopinavir = 15.48 + 1.59 * age 
[years], p = 0.044). For ritonavir, 16% of the interindividual variability in AUC0-12 were 
explained by the overall CYP3A activity as assessed by the oral midazolam clearance during 
ART (p = 0.019). This factor, together with digoxin Cmax before ART and grouped CYP2D6 
genotypes explained 43.9% of the interindividual variability in ritonavir Cmax (p = 0.003 for 
the entire model).  
 
Two patients did not participate in the second study period, one because of staying abroad for 
a longer time and the other because of intercurrent AIDS related diseases requiring treatment 
with drugs not allowed in the protocol. The study procedures and drugs were well tolerated.  
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Discussion  
In this study in HIV infected patients treated with ritonavir boosted lopinavir, lamivudine, and 
zidovudine, we quantified the extent of inhibition separately for hepatic and intestinal 
CYP3A, for CYP2D6, and for P-glycoprotein using a cocktail consisting of well-established 
phenotyping probes (18,20,26). For CYP3A and P-glycoprotein, this study confirmed the 
profound extent of inhibition by ritonavir boosted lopinavir already observed in healthy 
volunteers and in vitro (4,7,31). Additionally, we observed changes in dextromethorphan 
metabolism which indicated potent inhibition of CYP2D6. We attribute these effects mainly 
to ritonavir with some contribution of lopinavir, because for lamivudine and zidovudine, no 
interactions with the proteins studied here are reported in literature and their molecular 
structure does not suggest binding to CYPs or P-glycoprotein.  
 
The combined hepatic and intestinal CYP3A and the hepatic CYP3A activities decreased by 
81.5% and by 76.1%, respectively, which is similar to previous results in healthy volunteers: 
decreases by 92% and by 77%, respectively, were observed (4). In a study with seven patients 
receiving ritonavir in higher doses, the overall CYP3A activity was also distinctively 
decreased (7). A separate estimation of changes in intestinal CYP3A activity caused by 
ritonavir boosted lopinavir has not yet been reported. In the present study, an inhibition of 
intestinal CYP3A was observed in most patients, but in some participants, the parameter 
changed into the opposite direction (fig 2, mid panel), so that the mean decrease in intestinal 
CYP3A activity was modest. In vitro, ritonavir very potently inhibits CYP3A with IC50 values 
between 0.07 and 2.0 μM (32). In conclusion, interactions by ritonavir boosted lopinavir via 
CYP3A observed in studies with healthy volunteers will be the same in HIV infected patients.  
 
The changes in dextromethorphan based plasma pharmacokinetics in the 24 patients with at 
least one active CYP2D6 allele suggested that CYP2D6 activity was inhibited in the present 
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study. Not only the increase in the metabolic ratio, but also the increase in AUCdextromethorphan 
and the decrease in AUCdextrorphan support this conclusion. In a study with 13 healthy males 
who were phenotyped before and at the end of twice daily intake of 100 mg ritonavir for 2 
weeks, a modest inhibition of CYP2D6 was observed with desipramine, another CYP2D6 
substrate (mean 26% increase in desipramine AUC), but no change in CYP2D6 activity was 
noted using dextromethorphan-based urinary metabolic ratios (2). Another study in healthy 
volunteers did not find any influence of ritonavir boosted lopinavir on desipramine 
pharmacokinetics (3). In contrast, in vitro investigations suggested potent CYP2D6 inhibition 
by ritonavir (IC50: 2.5 μM) (32).  
 
The contradictory findings concerning CYP2D6 inhibition by ritonavir using the desipramine 
AUC and the urinary dextromethorphan / dextrorphan ratio (2) raise the question which 
metric most reliably reflects changes in CYP2D6 activity (33-35). While desipramine is a less 
frequently used CYP2D6 probe with limited applicability in a phenotyping cocktail, the 
urinary dextromethorphan ratio is dependent on urinary pH (36), and is not sensitive to detect 
minor changes (33). The “gold standard” for enzyme activity assessment would be the 
quantification of the CYP2D6 mediated fractional metabolic clearance. Since this parameter 
cannot be quantified directly, as an approximation, we decided to use the dextromethorphan / 
dextrorphan AUC ratio which has been proposed as a more sensitive parameter of CYP2D6 
activity than urine-based metrics (33), but also has some limitations (19). The relatively low 
within-subject variability in dextromethorphan pharmacokinetics in our study (e.g. 21.8% for 
the metabolic ratio) corroborates the validity of the approach chosen.  
 
Further evidence for an inhibition of CYP2D6 by ritonavir boosted lopinavir comes from case 
reports of unanticipated drug toxicity. In two reports, extrapyramidal toxicity of risperidone 
was described (37,38), which is to at least 80% metabolized via CYP2D6 (39). At least three 
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reports describe life-threatening toxicities of methylene-dioxy-methamphetamine (MDMA, 
ecstasy, reviewed in (40)). The first and rate-limiting step in MDMA biotransformation is 
mediated by CYP2D6 (41). Taken together, the present results support a relevant inhibition of 
CYP2D6 by ritonavir boosted lopinavir which may have clinically relevant implications for 
drugs with a narrow therapeutic index.  
 
The changes in AUC ratios in the four poor metabolizers, who do not express CYP2D6, 
cannot be attributed to CYP2D6 inhibition. Other pathways of metabolism and elimination of 
dextromethorphan become relevant if CYP2D6 activity is absent, like glucuronidation of me-
tabolites (19,42,43). Ritonavir inhibits glucuronidation (44), but induction of glucuronidation 
by ritonavir in steady-state has been described (45), and recently been shown in an interaction 
study with lamotrigine (46). However, the extent and direction of changes in the four poor 
metabolizers was highly variable, and the number was too small to draw conclusions.  
 
The 1.81-fold increase of digoxin AUC0-12 during antiretroviral therapy suggests that P-
glycoprotein activity was profoundly inhibited. A study in 12 healthy volunteers who received 
300 mg ritonavir twice daily for 11 days showed a 1.86-fold increase in digoxin AUC0-∞ (31). 
It may be concluded that higher doses of ritonavir do not lead to a more complete inhibition of 
P-glycoprotein. Additionally, orally administered digoxin appears to mainly quantify the 
intestinal P-glycoprotein activity (25-27).  
 
It has been postulated repeatedly that genetics, enzyme and transporter phenotypes, and other 
factors influence the variability in protease inhibitor pharmacokinetics. (4,6-9,11,32,47). In 
the present study, besides a small, but statistically significant, contribution of CYP2D6 
genotypes to the interindividual variability in ritonavir Cmax, we could not detect significant 
influences of genotypes on lopinavir or ritonavir pharmacokinetics. Interestingly, the overall 
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CYP3A activity influenced ritonavir exposure, indicating a dependency between the extent of 
CYP3A inhibition and ritonavir pharmacokinetics. However, none of the phenotypes assessed 
before treatment was predictive for the extent of inhibition during ART or for protease 
inhibitor pharmacokinetics, preventing dose individualization by phenotyping. Although 11% 
of the interindividual variability in lopinavir exposure was explained by age, this fraction may 
be too small for dose individualization. Previous investigations did not find relationships 
between age and single-time-point lopinavir plasma concentrations (48,49), but exposure is a 
more reliable target parameter to identify factors of influence on pharmacokinetics. It should 
be noted that we investigated patients, which may have introduced some additional variability 
and necessitated that the patients took lamivudine and zidovudine as part of their antiretroviral 
therapy. Additionally, as a function of variability and sample size, small, probably clinically 
not relevant influences may have been missed. Great care was taken that no potentially 
interacting medication was taken and that patients adhered to the standardization measures.  
 
In conclusion, an antiretroviral regimen containing ritonavir boosted lopinavir besides 
zidovudine and lamivudine inhibits the CYP2D6 dependent drug metabolism in HIV infected 
patients in addition to the pronounced inhibitions of CYP3A at both the intestinal and hepatic 
expression sites, and of (intestinal) P-glycoprotein. This underlines the potential risk of 
interactions between ritonavir boosted lopinavir and drugs with a narrow therapeutic index 
that are CYP2D6 substrates. The impact of genetic polymorphisms in CYP3A5, CYP2D6 and 
MDR1 on the pharmacokinetics of ritonavir boosted lopinavir appears negligible. 
Additionally, phenotyping of CYP3A, CYP2D6 and P-glycoprotein activity before initiation 
of the antiretroviral therapy was not useful to predict lopinavir and ritonavir pharmacokinetics 
a priori. Hence, the covariates and factors investigated do not contribute relevantly to the 
pharmacokinetic variability of ritonavir boosted lopinavir in HIV-infected patients. Selection 
of doses based on these parameters does not appear to be a promising approach. 
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Legends to figures:  
Figure 1: Mean midazolam plasma concentration time curve in 28 patients before (closed 
circles) and at least 14 days after the start (open circles) of an antiretroviral therapy containing 
400 mg lopinavir + 100 mg ritonavir twice daily. The patients received 1.5 mg midazolam 
orally and 1.0 mg intravenously 4 hours later. Error bars indicate standard deviations. 
 
Figure 2: Individual changes in CYP3A activity parameters in 28 HIV infected patients before 
and after start of an antiretroviral therapy including lopinavir 400 mg + ritonavir 100 mg 
(LPV / rtv) twice daily. Dashed lines indicate geometric means. Left panel: individual 
changes in midazolam clearance (hepatic CYP3A activity), mid panel: individual changes in 
intestinal midazolam availability (intestinal CYP3A activity), right panel: individual changes 
in oral midazolam clearance (intestinal and hepatic CYP3A activity, calculated as Cl / F).  
 
Figure 3: Mean dextromethorphan (upper panel, circles) and dextrorphan (lower panel, 
triangles) plasma concentration time curves in 24 patients harboring at least one active 
CYP2D6 allele before (closed symbols) and at least 14 days after the start (open symbols) of 
an antiretroviral therapy containing 400 mg lopinavir + 100 mg ritonavir twice daily. The 
patients received 30 mg dextromethorphan hydrobromide orally. Error bars indicate standard 
deviations. For visual clarity, the concentration time curves during antiretroviral therapy 
(open symbols) were moved 6 min. to the right.  
 
Figure 4: Individual changes in CYP2D6 activity parameters in 28 HIV infected patients 
before and after start of an antiretroviral therapy including lopinavir 400 mg + ritonavir 100 
mg twice daily. Dashed lines indicate geometric means. Genotypic poor metabolizers: open 
squares. All other genotypes: closed circles. Left panel: individual changes in 
dextromethorphan AUC0-12, mid panel: individual changes in dextrorphan AUC0-12, right 
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panel: individual changes in the metabolic ratio of molar dextromethorphan AUC0-12 / molar 
dextrorphan AUC0-12 (as the primary parameter of CYP2D6 activity). Please note the 
logarithmic scale of the y-axis.  
 
Figure 5: Mean digoxin plasma concentration time curves in 28 patients before (closed 
circles) and at least 14 days after the start (open circles) of an antiretroviral therapy containing 
400 mg lopinavir + 100 mg ritonavir twice daily. The patients received 0.5 mg digoxin orally 
at both occasions. Error bars indicate standard deviations.  
 
Figure 6: Individual changes in P-glycoprotein activity parameters in 28 HIV infected patients 
before and after start of an antiretroviral therapy including lopinavir 400 mg + ritonavir 100 
mg twice daily. Dashed lines indicate geometric means. Left panel: individual changes in 
digoxin AUC0-12, right panel: individual changes in digoxin Cmax. Please note the logarithmic 
scale of the y-axis.  
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Table 1: Demographic data, baseline characteristics (arithmetic means and ranges) and 
genotypes (absolute numbers) of 28 patients included in the analyses. Two patients dropped 
out due to reasons not related to the study, and have not been included in the calculations.  
Baseline characteristics Value 
Gender: 6 females, 22 males 
Ethnicity:  5 Africans, 23 Europeans 
Age:  40.1 (25 - 60) years  
Body weight:  72 (49 - 106) kg 
Body height:  174 (156 - 190) cm 
Body Mass Index:  23.7 (16.4-36.7) kg/m2 
Median CD4 count:  141 (10 - 330) cells / µL 
Median HIV - viral load:  179 (5 - 500) •103 copies / mL 
CYP3A5 genotype:  *1/*1: 5 (4 Africans, 1 European)  
*1/*3: 8 (1 African, 7 Europeans)  
*3/*3: 15 (15 Europeans) 
CYP2D6 genotype:  EM: 13 (3 Africans, 10 Europeans)  
IM: 10 (10 Europeans)  
PM: 4 (2 Africans, 2 Europeans)  
UM: 1 (1 European) 






CC: 28, CT: 0, TT: 0  
GG: 27; GA: 1; AA: 0  
AA: 24; AG: 4; GG: 0  
CC: 13; CT: 9; TT: 6  
GG: 9; GT: 10; TT: 6; GA: 2; TA: 1; AA: 0  
CC: 12; CT: 8; TT: 8  
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Table 2: Phenotyping metrics for intestinal and hepatic CYP3A, for CYP2D6 and for P-glycoprotein activity in 28 HIV-infected patients before and 
after 14 days of 400 mg lopinavir (LPV) and 100 mg ritonavir (rtv) twice daily. Geometric means and geometric coefficients of variation (CV) are 
shown. MID, midazolam, DEX, dextromethorphan, DOR, dextrorphan, PM, CYP2D6 genotypically poor metabolizers, non-PM, patients with at 
least one functionally active CYP2D6 allele.  
phenotyping metric enzyme / 
transporter 
n =  period without 
LPV/rtv 
CV [%] period with 
LPV/rtv 




hepatic MID clearance [L/h] hepatic CYP3A 28 24.5 24 %  5.9 55 %  0.239 0.199 – 0.288  
apparent oral MID clearance [L/h]  hepatic and 
intestinal CYP3A 
28 40.1 42 %  7.6 61 %  0.185 0.149 – 0.231  
intestinal MID availability [-]  intestinal CYP3A 28 0.78 24 %  0.87 37 %  1.121 0.995 – 1.263  
dextromethorphan AUC0-12 [ng/mL*h]   24 non PM 10.1 84 %  13.0  77 %  1.230 0.979 – 1.545  
dextromethorphan AUC0-12 [ng/mL*h]  4 PM 162.7 39 %  147.3  25 %  0.939  0.654 – 1.349  
dextrorphan AUC0-12 [ng/mL*h]   24 non PM 21.1 39 %  9.5  46 %  0.422 0.350 – 0.506  
dextrorphan AUC0-12 [ng/mL*h]   4 PM 5.7 370 % 4.0 199 %  0.693  0.317 – 1.518  
metabolic ratio AUCDEX / AUCDOR [-]  CYP2D6 24 non PM 0.45  90 %  1.31 78 %  2.920 2.313 – 3.685  
metabolic ratio AUCDEX / AUCDOR [-]   4 PM 27.12  464 % 34.74  171 %  1.337 0.413 – 4.335  
digoxin AUC0-12 [µg/L*h] P-glycoprotein 28 5.22 43 % 9.43 23 % 1.806 1.558 – 2.092  
digoxin Cmax [µg/L] P-glycoprotein 28 1.28 44 % 2.09 21 % 1.639 1.417 – 1.897  
* point estimate of the ratio of µ(period with LPV/rtv) / µ(period without LPV/rtv). 
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